TG Therapeutics (NASDAQ:TGTX) Sets New 52-Week High - Still a Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The company traded as high as $40.31 and last traded at $39.23, with a volume of 4876845 shares trading hands. The stock had previously closed at $38.44.

Analysts Set New Price Targets

A number of analysts have recently weighed in on TGTX shares. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Performance

The business has a fifty day simple moving average of $31.52 and a 200-day simple moving average of $28.83. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market cap of $5.82 billion, a P/E ratio of -370.56 and a beta of 2.30.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.50% of the stock is owned by insiders.

Hedge Funds Weigh In On TG Therapeutics

Several large investors have recently modified their holdings of the stock. Vermillion Wealth Management Inc. bought a new stake in TG Therapeutics in the 4th quarter worth about $30,000. Quadrant Capital Group LLC grew its stake in shares of TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 975 shares during the period. Blue Trust Inc. grew its stake in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares during the period. Finally, Jones Financial Companies Lllp grew its stake in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.